Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma

Zhang,Shan‑Shan; Tang,Jing; Yu,Shu‑Yi; Ma,Li; Wang,Feng; Xie,Shu‑Le; Jin,Long; Yang,Hong‑Yu

doi:10.3892/ol.2015.3274

Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma

Authors:
- Shan‑Shan Zhang
- Jing Tang
- Shu‑Yi Yu
- Li Ma
- Feng Wang
- Shu‑Le Xie
- Long Jin
- Hong‑Yu Yang
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, Department of Oral and Maxillofacial Surgery, Jingzhou Central Hospital, Jingzhou, Hubei 434000, P.R. China, Department of Bioscience and Technology, Modern Analytical Center, Central South University, Changsha, Hunan 410000, P.R. China, Discipline of Oral Rehabilitation, Faculty of Dentistry, The University of Hong Kong, Hong Kong, SAR 999077, P.R. China
Published online on: May 27, 2015 https://doi.org/10.3892/ol.2015.3274
Pages: 1063-1068

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the role of immune regulatory molecules B7-H3 [also known as cluster of differentiation 276] and triggering receptor expressed on myeloid cell‑like transcript‑2 (TLT‑2) in patients with oral squamous cell carcinoma (OSCC). Human OSCC samples were obtained from 76 patients (female, 32; male, 44; age range, 23‑81 years; median age, 50.9 years) that underwent resection for OSCC at Peking University Shenzhen Hospital (Shenzhen, China) between 2007 and 2010. In addition, control oral mucosal samples were obtained from 76 healthy individuals (female, 36; male, 40; age range, 21‑62 years; median age, 45.3 years) during wisdom tooth extraction. Protein and gene expression levels of B7‑H3 and TLT‑2 were determined by immunohistochemical analysis and reverse transcription‑polymerase chain reaction (RT‑PCR). In the healthy oral mucosa samples, B7‑H3 expression was identified to be weak, while the expression of TLT‑2 was only detected sporadically in the cell membrane and cytoplasm. By contrast, the two regulatory molecules were widely expressed in the aforementioned localizations in human OSCC specimens upon immunohistochemical examination. Furthermore, quantitative RT‑PCR confirmed the presence of significantly higher B7‑H3 and TLT‑2 expression levels in OSCC specimens compared with the oral mucosa of healthy individuals. The significantly higher expression levels of B7‑H3 and TLT‑2 in human OSCC specimens may indicate an inhibitory role of these molecules in the antitumoral immune response. To investigate interactions between these two molecules and individual antitumoral immune response in OSCC patients, prospective clinical studies with an adequate sample size are required.

View Figures

View References

1	Huang MN, Yu H and Moudgil KD: The involvement of heat-shock proteins in the pathogenesis of autoimmune arthritis: a critical appraisal. Semin Arthritis Rheum. 40:164–175. 2010. View Article : Google Scholar : PubMed/NCBI
2	North RJ and Bursuker I: Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 159:1295–1311. 1984. View Article : Google Scholar : PubMed/NCBI
3	Zang X and Allison JP: The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13:5271–5279. 2007. View Article : Google Scholar : PubMed/NCBI
4	Greenwald RJ, Freeman GJ and Sharpe AH: The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005. View Article : Google Scholar : PubMed/NCBI
5	Chen YW, Tekle C and Fodstad O: The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets. 8:404–413. 2008. View Article : Google Scholar : PubMed/NCBI
6	Chavin G, Sheinin Y, Crispen PL, et al: Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 15:2174–2180. 2009. View Article : Google Scholar : PubMed/NCBI
7	Crispen PL, Sheinin Y, Roth TJ, et al: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 14:5150–5157. 2008. View Article : Google Scholar : PubMed/NCBI
8	Roth TJ, Sheinin Y, Lohse CM, et al: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67:7893–7900. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yamato I, Sho M, Nomi T, et al: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer. 101:1709–1716. 2009. View Article : Google Scholar : PubMed/NCBI
10	Sun J, Chen LJ, Zhang GB, et al: Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 59:1163–1171. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, et al: Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 23:1104–1112. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zhang G, Xu Y, Lu X, Huang H, Zhou Y, Lu B and Zhang X: Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer. 66:245–249. 2009. View Article : Google Scholar : PubMed/NCBI
13	Hashiguchi M, Kobori H, Ritprajak P, et al: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA. 105:10495–10500. 2008. View Article : Google Scholar : PubMed/NCBI
14	Elango KJ, Anandkrishnan N, Suresh A, Iyer SK, Ramaiyer SK and Kuriakose MA: Mouth self-examination to improve oral cancer awareness and early detection in a high-risk population. Oral Oncol. 47:620–624. 2011. View Article : Google Scholar : PubMed/NCBI
15	Silverman S Jr: Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc. 132 (Suppl):7S–11S. 2001. View Article : Google Scholar : PubMed/NCBI
16	Regezi JA, Sciubba JJ and Jordan RCK: Oral Pathology: Clinical Pathologic Correlations. 5th. Elsevier Saunders; St. Louis, MO: 2007
17	Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000. View Article : Google Scholar : PubMed/NCBI
18	Carvalho AL, Magrin J and Kowalski LP: Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach. Oral Dis. 9:112–118. 2003. View Article : Google Scholar : PubMed/NCBI
19	Modjtahedi H: Molecular therapy of head and neck cancer. Cancer Metastasis Rev. 24:129–146. 2005. View Article : Google Scholar : PubMed/NCBI
20	De Roy PG: Helsinki and the Declaration of Helsinki. World Med J. 50:9–11. 2004.
21	O'Sullivan B and Shah J: New TNM staging criteria for head and neck tumors. Semin Surg Oncol. 21:30–42. 2003. View Article : Google Scholar : PubMed/NCBI
22	Shuyi Y, Feng W, Jing T, et al: Human beta-defensin-3 (hBD-3) upregulated by LPS via epidermal growth factor receptor (EGFR) signaling pathways to enhance lymphatic invasion of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 112:616–625. 2011. View Article : Google Scholar : PubMed/NCBI
23	Ohigashi Y, Sho M, Yamada Y, et al: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
24	Sun J, Xu K, Wu C, et al: PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens. 69:19–27. 2007. View Article : Google Scholar : PubMed/NCBI
25	Konishi J, Yamazaki K, Azuma M, et al: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
26	Hamanishi J, Mandai M, Iwasaki M, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8⁺ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 104:3360–3365. 2007. View Article : Google Scholar : PubMed/NCBI
27	Ghebeh H, Mohammed S, Al-Omair A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
28	Krambeck AE, Thompson RH, Dong H, et al: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA. 103:10391–10396. 2006. View Article : Google Scholar : PubMed/NCBI
29	Tringler B, Zhuo S, Pilkington G, et al: B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 11:1842–1848. 2005. View Article : Google Scholar : PubMed/NCBI
30	Nomi T, Sho M, Akahori T, et al: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
31	Zou W and Chen L: Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 8:467–477. 2008. View Article : Google Scholar : PubMed/NCBI
32	Chapoval AI, Ni J, Lau JS, et al: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI
33	Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y and Dong C: Murine B7-H3 is a negative regulator of T cells. J Immunol. 173:2500–2506. 2004. View Article : Google Scholar : PubMed/NCBI
34	Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K and Azuma M: Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 42:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
35	Leitner J, Klauser C, Pickl WF, et al: B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 39:1754–1764. 2009. View Article : Google Scholar : PubMed/NCBI